… Cetuximab Prog -PDX. Altogether, our findings indicate that TGF-beta-activated CAFs play
a role in limiting cetuximab … progression to cetuximab is associated with increased TGF-beta …

… carcinoma of the head and neck, as is cetuximab monotherapy. When cetuximab is added to
… or metastatic squamous cell carcinoma of the head and neck, the objective response rate is …

… effects of cetuximab and TGF-α, we measured the release of TGF-α into the medium as well
as cell-bound TGF-α during cetuximab incubation. For HN-24, the TGF-α concentration in the …

… between the autocrine activity of TGF-α and the E max for cetuximab (Fig. 2c). Obviously,
the correlation between TGF-α autocrine production and cetuximab sensitivity in this study is …

… of the head and neck, non-small cell lung cancer and pancreatic cancer when cetuximab is
used first or second line in combination with chemotherapy. Thus, cetuximab is emerging as …

… We studied the combination of bevacizumab and cetuximab in head and neck (SCC1)
and lung cancer (H226) xenograft model systems and demonstrated enhanced tumor growth …

… clinical trials demonstrated cetuximab efficacy in different … head and neck squamous cell
carcinoma in combination with radiation, and as monotherapy for recurrent and metastatic head …

… To date, the only survival benefit was seen with cetuximab, an … , was added to either cetuximab
or erlotinib in patients with … phase II evaluation of cetuximab alone versus cetuximab plus …

… Activated extracellular signal-related kinases: Association with epidermal growth factor
receptor/transforming growth factor α expression in head and neck squamous cell carcinoma and …

… cetuximab. In the present study, we have demonstrated that resistance to cetuximab in colorectal
cancer cells is mediated by TGF-α … be correlated with cetuximab resistance in head and …